CEO Dr. Igor Sherman Featured in CEOCFO Magazine
July 12, 2022
Recent Posts
- Alpha Cancer Technologies Presents New Data from ACT-903, an AFP-Maytansine Conjugate, in Online Publication at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
- Alpha Cancer Technologies Presentation at Gilmartin’s Private Company Showcase
- Alpha Cancer Technologies (ACT) to Participate in the Gilmartin Group Private Company Showcase
- Alpha Cancer Technologies (ACT) Publishes Pre-Clinical Study Results in Cancer Cell International Demonstrating Excellent Safety and Significant Anti-Tumor Activity from the Company’s Next Generation ADC, ACT-903
- Alpha Cancer Technologies Inc. Announces Acceptance of Abstract for Online Publication at the 2023 American Society of Clinical Oncology Annual Meeting